These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16197453)

  • 1. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
    Hubeek I; Peters GJ; Broekhuizen AJ; Sargent J; Gibson BE; Creutzig U; Kaspers GJ
    Br J Haematol; 2005 Oct; 131(2):219-22. PubMed ID: 16197453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
    Sargent JM; Elgie AW; Williamson CJ; Lewandowicz GM; Taylor CG
    Br J Cancer; 2001 Mar; 84(5):680-5. PubMed ID: 11237390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
    Walsby E; Lazenby M; Pepper C; Burnett AK
    Leukemia; 2011 Mar; 25(3):411-9. PubMed ID: 21212792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
    Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
    Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
    Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W
    Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside.
    Elmoneim AA; Heuston E; Wai DH; Triche T; Arceci RJ
    Anticancer Res; 2016 Feb; 36(2):691-6. PubMed ID: 26851026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
    Hubeek I; Peters GJ; Broekhuizen R; Zwaan CM; Kaaijk P; van Wering ES; Gibson BE; Creutzig U; Janka-Schaub GE; den Boer ML; Pieters R; Kaspers GJ
    Haematologica; 2006 Jan; 91(1):17-23. PubMed ID: 16434366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML.
    Sargent JM; Elgie AW; Williamson CJ; Taylor CG
    Adv Exp Med Biol; 1999; 457():567-70. PubMed ID: 10500835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.
    Wang Z; Van Tuyle G; Conrad D; Fisher PB; Dent P; Grant S
    Cancer Res; 1999 Mar; 59(6):1259-67. PubMed ID: 10096557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia.
    Sargent JM; Williamson CJ; Hubeek I; Elgie AW; Taylor CG; Den Boer ML; Peters GJ; Kaspers GL
    Oncol Rep; 2003; 10(6):2027-31. PubMed ID: 14534738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs.
    Freund A; Boos J; Harkin S; Schultze-Mosgau M; Veerman G; Peters GJ; Gescher A
    Eur J Cancer; 1998 May; 34(6):895-901. PubMed ID: 9797704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
    Momparler RL; Côté S; Momparler LF
    Leuk Res; 2013 Aug; 37(8):980-4. PubMed ID: 23660386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amidox, an inhibitor of ribonucleotide reductase, potentiates the action of Ara-C in HL-60 human promyelocytic leukemia cells.
    Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Fritzer-Szekeres M; Szekeres T
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1541-4. PubMed ID: 15571294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
    Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ
    Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
    Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CB; Sandhow L; Kutzner J; Hed Myrberg I; Bunten SS; Axelsson H; Zhang SM; Rasti A; Mäkelä P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtiö J; Rassidakis GZ; Pokrovskaja Tamm K; Warpman-Berglund U; Heyman M; Grandér D; Lehmann S; Lundbäck T; Qian H; Henter JI; Schaller T; Helleday T; Herold N
    EMBO Mol Med; 2020 Mar; 12(3):e10419. PubMed ID: 31950591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin.
    Fram RJ; Kufe DW
    Cancer Res; 1982 Oct; 42(10):4050-3. PubMed ID: 6809309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.